{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'Urine collection for urinalysis, possible reflex testing for abnormal GGT, AST, or', 'ALT and urine pregnancy test for female subjects of childbearing potential', 'Review of concomitant medications and AEs', 'Review of HAE attack diary completion and study drug compliance', 'Study drug accountability and dispensing (collection only at Week 144)', 'During the Part 3 dosing period, investigator confirmation of HAE attacks recorded in the diary', 'is not required. The diary should be reviewed with the subject at all study visits. Any', 'noncompliance will warrant contact with the subject.', 'At all clinic visits, sites in Europe will dispense urinary pregnancy tests to subjects who are', 'women of childbearing potential. These will be performed by the subject at home at monthly', 'intervals between study visits.', '10.3.5.2. Week 52, 56, 64, 68, 76, 80, 88, and 92 Phone Calls', 'The Investigator (or designee) must call and talk to the subject once during Weeks 52, 56, 64, 68,', '76, 80, 88, and 92; alternative forms of interactive communication such as returned email and', 'cellular text correspondence are acceptable. During all calls, the Investigator (or designee) will', \"assess the subject's overall wellbeing, discuss compliance (if applicable), proper recording of\", 'attack details (if applicable), or any usability issues with the diary.', '10.3.6.', 'Follow-up/Early Termination Visit', 'Following completion of study drug on Week 144 or earlier, all subjects will return to the clinic', '3 weeks post-last dose (+ 1 week) for their follow-up assessments.', 'The following assessments will be performed for study completers at the follow-up visit held', 'approximately 3 weeks following the last dose of study drug. These assessments will also be', 'conducted at an early termination visit for those withdrawing consent during any study part (see', 'Section 8.3.1):', 'Subject weight', 'Targeted physical examination', 'Vital signs (blood pressure and pulse rate)', '12-lead ECG', 'Blood collection for clinical chemistry, hematology, coagulation, Troponin I and', 'Troponin T, NGAL, and CK-MB', 'Urine collection for urinalysis, possible reflex testing for abnormal GGT and urine', 'pregnancy test for female subjects of childbearing potential', 'Review of concomitant medications and AEs', 'Review and collection of diary', 'Blood for plasma PD and PK (early termination visit prior to Week 48 only)', '70']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'If an AE is ongoing at the last follow-up visit, additional clinic visit(s) or telephone contact(s)', 'may be warranted (see Section 12.1.2).', '11.', 'ASSESSMENTS', 'The schedule of procedures and assessments to be conducted throughout the study are outlined in', 'Table 2, Table 3, and Table 4 (for Parts 1, 2, and 3, respectively) with details on the conduct of', 'the procedures/assessments provided below.', '11.1.', 'Chronology of Assessments', 'The following chronology of events should be adhered to during the scheduled visits, as', 'applicable:', 'QoL/health outcome questionnaires: obtain prior to all clinic procedures', 'ECGs: obtain prior to vital signs and blood specimen collection', 'Vital signs: obtain prior to blood specimen collection', 'Randomization and study drug dispensing/dosing: end of the visit', '11.2.', 'Investigator-Completed Assessments', 'Demographic information, including year of birth, sex, race, and ethnicity will be captured for', 'each subject participating in the study at the screening visit. Medical and medication history will', 'be captured at the screening visit and updated at baseline. Subject participation in a prior', 'BCX7353 study will be captured (eg, study, previous subject number).', 'Contraceptive methods enabling eligibility will be captured in source documentation at the', 'screening visit. Contraceptive methods and/or lifestyle should be reviewed throughout the study', 'to ensure they remain appropriate for the subject.', '11.2.1.', 'HAE Medical and Medication History', 'An HAE medical history questionnaire provided by the Sponsor will be completed at screening.', 'All questions should be completed by the Investigator (or designee) from historical source', 'documentation when available, with subject input as necessary to complete the remaining', 'questions. The completed HAE Medical History Questionnaire will be considered a source', 'document and must be entered in the CRF in full to enable randomization (see Section 9.3.2).', '11.2.2.', 'Physical Examination', 'A full physical examination will be conducted at Screening, Baseline, and at Week 24. All other', 'physical examinations will be abbreviated (ie, targeted or symptom-directed) to include, at a', 'minimum, evaluation of any new signs or symptoms.', 'Genitourinary and breast examinations may be omitted when not required by normal site', 'practice.', '71']\n\n###\n\n", "completion": "END"}